Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial
American Journal of Nephrology · 2025
DOI: 10.1159/000546615 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Charles W Bishop und 6 weiteren Autor:innen. Beteiligte Einrichtung: OPKO Health, Miami, Florida, USA, cbishop@opko.com. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperparathyroidism, Secondary, Vitamin D, Kidney Failure, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Serum concentrations of 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D) decline as chronic kidney disease (CKD) advances, becoming insufficient without effective vitamin D repletion and driving onset of secondary hyperparathyroidism (SHPT). Randomized controlled trials (RCTs) in non-dialysis CKD patients have established that extended-release calcifediol (ERC) effectively raises 25D and 1,25D and reduces elevated intact parathyroid hormone (iPTH) despite the progressive loss of renal cytochrome P450 25D-1α-hydroxylase (CYP27B1), suggesting its potential usefulness in treating SHPT in end-stage kidney disease (ESKD).
Methods
This pilot RCT explored the safety and efficacy of oral ERC to raise serum total 25D to ≥50 ng/mL, normalize circulating 1,25D, and reduce elevated iPTH in ESKD patients requiring regular hemodialysis (HD). Forty-four adults from 13 US clinics requiring HD three times per week were washed out from iPTH-lowering therapies and randomized 3:1 to 26 weeks of treatment with ERC (300 µg/HD) or placebo. Participants had a mean age of 56.4 ± 11.6 years, body mass index of 32.7 ± 8.1 kg/m2, 46% were female, 68% black, 30% white, and 24% Hispanic. At randomization, iPTH had to be 300 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OPKO Health, Miami, Florida, USA, cbishop@opko.com.
- OPKO Health, Miami, Florida, USA.
- Next Generation Clinical Research, Fitchburg, Wisconsin, USA.
- David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
- NorthShore University Health System-University of Chicago, Pritzker School of Medicine, Evanston, Illinois, USA.
Zitieren
APA
Bishop, C. W., Ashfaq, A., Choe, J., Strugnell, S. A., Johnson, L. L., Norris, K. C., & Sprague, S. M. (2025). Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. American Journal of Nephrology. https://doi.org/10.1159/000546615
Vancouver
Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, et al. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. American Journal of Nephrology. 2025. doi:10.1159/000546615
BibTeX
@article{Bishop2025,
author = {Bishop, Charles W and Ashfaq, Akhtar and Choe, John and Strugnell, Stephen A and Johnson, Laura L and Norris, Keith C and Sprague, Stuart M},
title = {Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial},
journal = {American Journal of Nephrology},
year = {2025},
doi = {10.1159/000546615}
}
EUVIMED